关键词:
  首页 > 美迪医讯 > CoTherix公司推出治疗肺动脉高压的Ventavis  

CoTherix公司推出治疗肺动脉高压的Ventavis

【 2005-06-09 发布 】 美迪医讯
美迪网领先的医疗器械电子商务平台

在2005年5月美国胸部疾病学会国际会议上宣读的一项研究结果,吸入性药物iloprost有利于肺动脉高压患者。

Ventavis(iloprost)吸入溶液是由CoTherix公司推向市场的,已经获得美国食品药品管理局的批准。Iloprost是合成的化合物,与prostacyclines相似。Ventavis是Schering公司的商标。

一项使用iloprost治疗肺动脉高压的长期临床试验显示:该药对III级和IV级患者十分有效,为期2年的资料显示出了持久的临床作用。在维持临床作用方面无须显著增加剂量。原发性或者特发性肺动脉高压的患者两年生存率为91%,而未治疗历史对照人群的预期生存率为63%。最严重的不良事件是心脏衰竭。

在另外一项IV级肺动脉高压患者的临床试验中,比较了吸入iloprost与安慰剂的作用。使用吸入iloprost药物组患者比安慰剂组患者的作用明显要好。肺动脉高压患者iloprost的治疗反应率为17%,而安慰剂组是2%。

Graz医科大学的Horst Olschewski医生报道了这些资料,他说:“间断使用iloprost药物治疗提高了运动能力和肺脏血液动力学,减少了出现耐受和反弹的危险。同时还避免了长期留置导管的麻烦和出现并发症。”

Therapy for Pulmonary Arterial Hypertension
 
The inhaled drug iloprost benefits patients with pulmonary arterial hypertension (PAH), according to study results announced at the American Thoracic Society International Conference in San Diego (CA, USA) in May 2005.

The Ventavis (iloprost) inhalation solution marketed by CoTherix, Inc. (South San Francisco, CA, USA) has been cleared by the U.S. Food and Drug Administration (FDA). Iloprost is a synthetic compound similar to prostacyclines. Ventavis is a trademark of Schering AG (Berlin, Germany).

One study of long-term treatment for PAH with iloprost showed that the drug was effective for class III and IV patients, with two-year data suggesting sustained clinical benefit. No significant dose increase was required to maintain clinical benefit. Patients with primary or idiopathic pulmonary hypertension had a two-year survival rate of 91%, compared to a predicted survival of 63% for an untreated historical cohort. Heart failure was the most common serious adverse event.

In another study of patients with class IV pulmonary hypertension, inhaled iloprost was compared to placebo. Patients in the inhaled iloprost group performed significantly better than those in the placebo group. The response rate among PAH patients treated with iloprost was 17%, compared to 2% for those treated with placebo.

“Intermittent therapy with inhaled iloprost improved exercise capacity and pulmonary hemodynamics while reducing the risk of developing tolerance and rebound,” noted Horst Olschewski, M.D., Medical University of Graz (Austria), who presented the data. “It also avoids the inconvenience and complications associated with chronic indwelling catheters.”

/**/
收藏本文到: Google书签 Digg Live Bookmark Yahoo书签 Facebook 百度搜藏 新浪ViVi 365Key网摘 天极网摘 和讯网摘 POCO网摘 QQ书签

  《美迪医讯》欢迎您参与新闻投稿,业务咨询: 美迪医疗网业务咨询

我要评论:《CoTherix公司推出治疗肺动脉高压的Ventavis》
匿名发表 我的名字: Email: 验证码: 点击可刷新
 
    

  更多关于 CoTherix公司,肺动脉高压,Ventavis  的新闻

合作支持:中华医学会 | 中华医院管理学会 | 国家食品药品监督管理家用护理器械商城 | 国药励展展览有限责任公 | 医学装备协会
刊登广告 | 友情链接 | 广告代理商加盟 | 关于美迪 | 法律声明 | 隐私保护 | 网站地图
把美迪网放进收藏夹  把美迪医疗网介绍给我的朋友  给美迪医疗网留言
美迪医疗网广告业务联系:021-51601230 产品咨询业务联系:021-51601230 传真:021-56532303    美迪医疗网业务咨询
互联网药品信息服务许可证:(沪)-经营性-2009-0003   中华人民共和国电信与信息服务业务经营许可证:(沪)B2-20090029 沪ICP备14001091号-8
 
公安备案号 31010602000199 医疗器械经营许可证: 沪静药监械经营许20210003号 第二类医疗器械经营备案凭证: 沪静药监械经营备20220042号
营业执照:统一社会信用代码91310108676284138X互联网药品信息服务资格书:(沪)-非经营性-2023-0081
消防排烟风机 华创商务网
美迪医疗网广告业务联系:021-51601230  产品咨询业务联系:021-51601230 传真:021-56532303   美迪医疗网产品咨询 本QQ仅咨询广告和会员业务,不咨询产品和药品等业务美迪医疗网推广业务咨询